Featured

Former hedge fund manager purchases AIDS drug, raises price from $13.50 to $750 per tablet

A former hedge fund manager turned pharmaceutical entrepreneur has purchased the rights to a 62-year-old drug that fights parasitic infections, raising the cost from $13.50 per tablet to $750 overnight.

According to the New York Times, a former hedge fund manager turned pharmaceutical entrepreneur has purchased the rights to a 62-year-old drug that fights parasitic infections, raising the cost from $13.50 per tablet to $750 overnight.

Martin Shkreli, 32, the founder and chief executive of Turing Pharmaceuticals, bought the drug Daraprim for $55 million on the same day his company announced it had raised $90 million from Shkreli and other investors in its first round of financing.

From The Raw Story:

Daraprim is used for treating toxoplasmosis — an opportunistic parasitic infection that can cause serious or even life-threatening problems in babies and for people with compromised immune systems like AIDS patients and certain cancer patients — that sold for slightly over $1 a tablet several years ago. Prices have increased as the rights to the drug have been passed from one pharmaceutical company to the next, but nothing like the almost 5,500 percent increase since Shkreli acquired it.

“What is it that they are doing differently that has led to this dramatic increase?” Dr. Judith Aberg, chief of infectious diseases at the Icahn School of Medicine at Mount Sinai asked.

Shkreli says Turing will put the extra profits back into research to develop better treatments for toxoplasmosis that have fewer side effects.

“This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business,” Shkreli explained, saying the drug is used short term and that the new price is competitive with other drugs

“It really doesn’t make sense to get any criticism for this,” he added.

Screen Shot 2015-09-21 at 10.41.43 AM

Shkreli, via Twitter

According to the Times report, this isn’t the first time Shkreli has come under fire for his methods.

He started MSMB Capital, a hedge fund company, in his 20s and drew attention for urging the Food and Drug Administration not to approve certain drugs made by companies whose stock he was shorting.

In 2011, Mr. Shkreli started Retrophin, which also acquired old neglected drugs and sharply raised their prices. Retrophin’s board fired Mr. Shkreli a year ago. Last month, it filed a complaint in Federal District Court in Manhattan, accusing him of using Retrophin as a personal piggy bank to pay back angry investors in his hedge fund.

Mr. Shkreli has denied the accusations. He has filed for arbitration against his old company, which he says owes him at least $25 million in severance. “They are sort of concocting this wild and crazy and unlikely story to swindle me out of the money,” he said.

Regarding Shkreli’s claim that the excess profits will go back to research, doctors say that isn’t needed.

“I certainly don’t think this is one of those diseases where we have been clamoring for better therapies,” said Dr. Wendy Armstrong, professor of infectious diseases at Emory University in Atlanta.

Featured image via Twitter

Facebook Comment
9 Comments

9 Comments

  1. Team Paulo

    September 21, 2015 at 8:17 pm

    scumbag.

  2. Read More

    September 21, 2015 at 8:29 pm

    He is definitely a lying little prick. This should be against the law.

  3. jan

    September 21, 2015 at 8:42 pm

    Please karma kick this guys ass. Give him what he deserves

  4. Kristian Colasacco

    September 21, 2015 at 9:57 pm

    I suspect this guy gets a lot of wedgies.

  5. Oskar Mazeroth

    September 22, 2015 at 1:07 am

    How is it that a drug that is 62 years old is still protected by patent? I thought the duration of patent protection was 17years. What loophole allows this situation to exist?

  6. Robin

    September 22, 2015 at 6:18 pm

    May he reap what he sows. Karma would be this vile pig contracting a disease and losing every dime he has in pursuit of a cure or medication that would prolong his pitiful life.

  7. Mike Akers

    September 24, 2015 at 3:04 am

    Yeah, I’m confused as to how a different company can’t just make the same drug in a generic for the appropriate price. Not really a question of why it is morally reprehensible; that universally goes without saying. I want to know why this is even possible to do from an economics standpoint, even if it were hypothetically ethical.

  8. Pingback: Hackers just released the home address and phone number of price-gouging pharma CEO Martin Shkreli | we must know

  9. DeathToYuppieScum

    July 10, 2016 at 2:21 am

    Tread lightly Shkreli, the Wrath of God is close behind you, and, be it through a bullet, or a knife to your throat, his judgement shall fall upon you, you filthy misbegotten infadel!

Leave a Reply

Your email address will not be published.

To Top